|
Home - Press Releases 2007
 |
Press Releases 2007 |
 |
 |
| FOR IMMEDIATE RELEASE |
Contact: |
Clinton Abbott
Investor Relations
(800) 545-9960 |
Allergy Research Group, Inc. Reports Third Quarter Results
ALAMEDA---------November 14, 2007--------Allergy Research Group, Inc. (OTCBB:ALRG) today announced financial results for the quarter ending September 30, 2007.
ALRG announces revenues of $4,319,664 for the quarter ended September 30, 2007, an increase of 6% compared to $4,091,460 for the same period last year. The third quarter increase was driven by increased sales to our wholesale customers and to distributors. We attribute the third quarter increase in sales to a combination of the results of our promotional efforts and the upward trend ordering patterns of the distributors.
Cost of sales increased $104,482 to $2,633,782 for the quarter ended September 30, 2007, compared to $2,529,300 for the quarter ended September 30, 2006. The increase corresponds to the increase in sales. Gross profit margins were approximately 39% for 2007 and 38% for 2006. Gross profit margins increased approximately 1% for the period over period comparison primarily as a result of increased prices on 50 items beginning in February 2007.
Net earnings after tax for September 30, 2007 and 2006 was $339,399 and $291,434, respectively. Net earnings increased in the third quarter due to the increase in sales and interest income offset by increased general and administrative costs.
Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].
About Allergy Research Group, Inc.
Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.
# # #
Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, dependence on key personnel, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department or via the SEC’s website located at www.sec.gov.
(Top)
|
| FOR IMMEDIATE RELEASE |
Contact: |
Clinton Abbott
Investor Relations
(800) 545-9960 |
Allergy Research Group, Inc. Reports Second Quarter Results
ALAMEDA---------August 14, 2007--------Allergy Research Group, Inc. (OTCBB:ALRG) today announced financial results for the quarter ending June 30, 2007.
ALRG announces revenues of $4,072,470 for the quarter ended June 30, 2007, an increase of 2% compared to $3,996,496 for the same period last year. The increase in sales is primarily attributable to increased sales to our wholesale customers and to distributors resulting from our promotional efforts and the up side of the ordering patterns of the distributors. Sales to distributors had decreased in the first quarter and bounced back in the second quarter.
Cost of sales increased $15,219 to $2,482,247 for the quarter ended June 30, 2007, compared to $2,467,028 for the quarter ended June 30, 2006. The increase corresponds to the increase in sales. Gross profit margins were approximately 39% for 2007 and 38% for 2006. Gross profit margins increased approximately 1% for the period over period comparison primarily as a result of increased prices on 50 items during February 2007.
Net earnings after tax for June 30, 2007 and 2006 was $242,116 and $257,856, respectively. The decrease is due primarily to increased operating expenses.
Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].
About Allergy Research Group, Inc.
Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.
# # #
Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, dependence on key personnel, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department or via the SEC’s website located at www.sec.gov.
(Top)
|
| FOR IMMEDIATE RELEASE |
Contact: |
Clinton Abbott
Investor Relations
(800) 545-9960 |
Allergy Research Group, Inc. Reports First Quarter Results
ALAMEDA---------May 15, 2007--------Allergy Research Group, Inc. (OTCBB:ALRG) today announced financial results for the quarter ending March 31, 2007.
ALRG announces revenues of $4,086,717 for the quarter ended March 31, 2007, a decrease of 4% compared to $4,265,527 for the same period last year. The decrease in sales is a result of decreased sales to our distributors and retail customers. Sales to professional accounts also decreased but to a lesser degree. The decrease in sales is affected by the ordering patterns of our customers, as evidenced by an 8% increase in orders placed during April 2007 when compared to 2006. We cannot predict yet what the effect of those increased orders will be on our overall financial results for the second quarter, as orders may continue to fluctuate throughout the period.
Cost of sales decreased $124,724 to $2,505,786 for the quarter ended March 31, 2007, compared to $2,630,510 for the quarter ended March 31, 2006. The decrease corresponds to the decrease in sales. Gross profit margins were approximately 39% for 2007 and 38% for 2006. Gross profit margins increased approximately 1% for the period over period comparison primarily as a result of increased prices on 50 items during February 2007.
Net earnings after tax for March 31, 2007 and 2006 was $281,908 and $325,683, respectively. The decrease is due primarily to decreased sales and increased operating expenses.
Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].
About Allergy Research Group, Inc.
Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.
# # #
Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, dependence on key personnel, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department or via the SEC’s website located at www.sec.gov.
(Top)
|
| FOR IMMEDIATE RELEASE |
Contact: |
Clinton Abbott
Investor Relations
(800) 545-9960 |
Allergy Research Group, Inc. Reports Increased Revenues For 2006
ALAMEDA---------March 29, 2007--------Allergy Research Group, Inc. (OTCBB:ALRG) today announced financial results for the year ending December 31, 2006.
ALRG announces revenues of $16,273,465 for the year ended December 31, 2006, an increase of 2% compared to $15,911,221 for the year ending December 31, 2005. The increase in sales is primarily due to the introduction of new products.
“We plan to increase our efforts to expand sales by executing additional promotional activities with selected major accounts in 2007 and utilizing the knowledge and skills of our existing staff,” said Chief Executive Officer and Chairman, Dr. Stephen A. Levine, Ph.D.
Cost of sales increased $548,444 to $10,193,737 for the year ended December 31, 2006, compared to $9,645,293 for the year ended December 31, 2005. The increase in sales plus increased cost of materials and increased shipping costs caused the increase in cost of sales. Gross profit margins were approximately 37% for 2006 and 39% for 2005. In addition to the increased cost of materials, there is a downward pressure on margins due to the changing mix between wholesale customers and distributors and due to the introduction of lower margin items. We responded to the decrease in margins by raising prices on approximately 50 items to roll out between February and April 2007.
Net income after tax for December 31, 2006 and 2005 was $1,095,976 and $1,208,869, respectively. The decrease is primarily due to the decrease in gross profit.
Complete copies of the company's financial statements, including notes to the financials, can be found on its website at www.nutricology.com [click here].
About Allergy Research Group, Inc.
Allergy Research Group, Inc. is an innovative leader in nutraceutical research and product formulation. Since its inception in 1979, the company has been noted for quality, hypoallergenic nutritional supplements and supplies products to physicians and healthcare practitioners worldwide.
# # #
Except for historical information contained herein, this release contains, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, forward-looking statements that are based on management's beliefs and assumptions, current expectations, estimates and projections. Many of the factors that will determine the Company's financial results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and therefore actual results may differ materially. The Company disclaims any obligation to update any forward-looking statements whether as a result of new information, future events, or otherwise. Important factors and risks that may affect future results include but are not limited to: the impact of competitive products, changes in law and regulations, adequacy and availability of insurance coverage, availability of raw materials, dependence on distributors and customers, dependence on key personnel, litigation, limitations on future financing, the effect of adverse publicity, uncertainties relating to acquisitions, managing and maintaining growth, customer demands, as well as other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available upon request from the Company's investor relations department or via the SEC’s website located at www.sec.gov.
(Top)
|
| |
 |
|
 |
|
|
Interview with Founder
